How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

550 results for

Famciclovir

by
...
Latest & greatest
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

521. Acute pain in herpes zoster: the famciclovir database project. (PubMed)

Acute pain in herpes zoster: the famciclovir database project. The results of a considerable number of recent prospective studies have demonstrated that greater acute pain severity in herpes zoster patients is associated with a significantly greater risk of developing postherpetic neuralgia (PHN). Only a few studies have examined the relationships between acute pain severity and demographic characteristics and clinical features of patients with herpes zoster, however, and the results (...) of these studies have been inconsistent. To clarify these relationships, data from 1778 herpes zoster patients studied within 72 h of rash onset in four clinical trials of the antiviral agent famciclovir were examined. Univariate and multivariate analyses indicated that greater acute pain severity was significantly associated with greater age, female sex, greater rash severity, the presence of a prodrome, and primary involvement of non-trigeminal dermatomes. These results demonstrate that three

2001 Pain

522. Famciclovir effective in suppressing recurrent genital herpes. (PubMed)

Famciclovir effective in suppressing recurrent genital herpes. 11361692 1997 05 08 2018 11 30 1087-2914 10 2 1996 Apr AIDS patient care and STDs AIDS Patient Care STDS Famciclovir effective in suppressing recurrent genital herpes. 130 eng Clinical Trial News Randomized Controlled Trial United States AIDS Patient Care STDS 9607225 1087-2914 0 Antiviral Agents 452-06-2 2-Aminopurine QIC03ANI02 Famciclovir X 2-Aminopurine analogs & derivatives therapeutic use Antiviral Agents therapeutic use (...) Double-Blind Method Famciclovir Herpes Genitalis drug therapy Humans Recurrence 1996 4 1 0 0 2001 5 22 10 1 1996 4 1 0 0 ppublish 11361692

1997 AIDS patient care and STDs Controlled trial quality: uncertain

523. Should we offer famciclovir to patients with new-onset herpes zoster? (PubMed)

Should we offer famciclovir to patients with new-onset herpes zoster? 10349063 1999 06 14 2018 12 01 0008-350X 45 1999 May Canadian family physician Medecin de famille canadien Can Fam Physician Should we offer famciclovir to patients with new-onset herpes zoster? 1195-6 Martin F F Kildonan Medical Centres, Winnipeg, Man. Evans M F MF eng Clinical Trial Comparative Study Journal Article Randomized Controlled Trial Canada Can Fam Physician 0120300 0008-350X 0 Antiviral Agents 0 Placebos 0 (...) Prodrugs 452-06-2 2-Aminopurine QIC03ANI02 Famciclovir IM 2-Aminopurine administration & dosage analogs & derivatives therapeutic use Acute Disease Age Factors Antiviral Agents administration & dosage therapeutic use Double-Blind Method Evaluation Studies as Topic Famciclovir Herpes Zoster drug therapy Humans Middle Aged Placebos Prodrugs Time Factors 1999 6 1 1999 6 1 0 1 1999 6 1 0 0 ppublish 10349063 PMC2328600 Br J Dermatol. 1987 Oct;117(4):495-501 3314973 Psychosomatics. 1990 Summer;31(3):287-92

1999 Canadian family physician Medecin de famille canadien Controlled trial quality: uncertain

524. Famciclovir for the treatment of herpes zoster. (PubMed)

Famciclovir for the treatment of herpes zoster. 8627199 1996 06 27 2018 11 30 0094-3509 42 4 1996 Apr The Journal of family practice J Fam Pract Famciclovir for the treatment of herpes zoster. 350 Gordon A A eng Clinical Trial Journal Article Multicenter Study Randomized Controlled Trial United States J Fam Pract 7502590 0094-3509 0 Antiviral Agents 452-06-2 2-Aminopurine QIC03ANI02 Famciclovir AIM IM 2-Aminopurine analogs & derivatives therapeutic use Acute Disease Adult Antiviral Agents (...) therapeutic use Double-Blind Method Famciclovir Herpes Zoster complications drug therapy Herpesvirus 3, Human drug effects Humans Neuralgia drug therapy etiology prevention & control Treatment Outcome 1996 4 1 1996 4 1 0 1 1996 4 1 0 0 ppublish 8627199

1996 The Journal of family practice Controlled trial quality: uncertain

525. Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. (PubMed)

Famciclovir, a new oral antiherpes drug: results of the first controlled clinical study demonstrating its efficacy and safety in the treatment of uncomplicated herpes zoster in immunocompetent patients. This multicentre, double-blind, double-dummy, randomised study was undertaken to compare the efficacy and tolerability of famciclovir administered at 250 mg, 500 mg and 750 mg three times daily with acyclovir 800 mg five times daily for the treatment of acute uncomplicated herpes zoster (...) in immunocompetent adults. A total of 545 patients participated in this trial. Treatment was initiated within 72 h of the onset of the zoster rash and was continued for seven days. When treatment was initiated within 72 h, famciclovir was found to be as effective as acyclovir at all dose levels for cutaneous lesion healing as demonstrated by the median times to full crusting, cessation of new lesion formation, loss of vesicles and loss of crusts; time to loss of acute pain was comparable in patients receiving

1994 International journal of antimicrobial agents Controlled trial quality: uncertain

526. Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. (PubMed)

Linear pharmacokinetics of penciclovir following administration of single oral doses of famciclovir 125, 250, 500 and 750 mg to healthy volunteers. Twenty healthy male volunteers received single oral doses of famciclovir (125-750 mg), in a randomized, single-blind, crossover study. Plasma and urine concentrations of penciclovir and its 6-deoxy precursor, BRL 42359, were determined and penciclovir plasma concentration-time data submitted to model-independent pharmacokinetic analysis. Peak plasma (...) concentrations of penciclovir were obtained at median times of 0.5-0.75 h after dosing. The areas under the concentration versus time curves (AUC) and the peak penciclovir concentration (Cmax) increased linearly with dose of famciclovir. Time to Cmax, elimination half-life, urinary recovery and renal clearance of penciclovir did not change with increasing dose. Famciclovir was excreted via the kidneys as penciclovir (60%) and BRL 42359 (5%), respectively. Famciclovir was well tolerated by all subjects

1994 The Journal of antimicrobial chemotherapy Controlled trial quality: uncertain

527. Efficacy of famciclovir in the treatment of herpes zoster. (PubMed)

Efficacy of famciclovir in the treatment of herpes zoster. Although vidarabine was the first systemic antiviral drug for the treatment of acute herpes zoster, the agent now used most frequently is acyclovir, a far safer drug that became available a decade ago. However, even with widespread use of acyclovir, postherpetic neuralgia (PHN) remains a principal cause of postinfectious morbidity. Newer antiviral agents, such as famciclovir and valacyclovir, have recently been introduced (...) for the treatment of uncomplicated herpes zoster. In a double-blind, randomized study, 500 mg of famciclovir three times daily for 7 days was compared with placebo; in a second study, 500 mg of famciclovir three times daily for 7 days was compared with 800 mg of acyclovir five times daily for 7 days. Famciclovir significantly reduced duration of viral shedding (P = 0.0001) and accelerated lesion resolution compared with placebo. Famciclovir was comparable to acyclovir for these acute parameters. Most

1996 Seminars in dermatology Controlled trial quality: uncertain

528. Safety of famciclovir in patients with herpes zoster and genital herpes. (PubMed)

Safety of famciclovir in patients with herpes zoster and genital herpes. Safety reporting from individual ongoing and completed clinical studies has demonstrated that famciclovir, the well-absorbed oral form of the antiherpesvirus agent penciclovir, has been well tolerated by more than 3,000 individuals worldwide. An integrated safety evaluation has been performed and includes over 1,600 patients from 11 completed, randomized, double-blind clinical trials and 2 open trials. The famciclovir (...) population consisted of 816 herpes zoster patients (four trials), 409 patients with acute genital herpesvirus infections (seven trials), and 382 patients from two genital herpes suppression studies. Overall, the famciclovir-treated patient population was 57.7% female and ranged in age from 15 to 102 years (mean, 42.6 years), with 31.2% aged 50 years or more and 15.7% aged 65 years or more. The mean duration of exposure to famciclovir was 28.8 days (5.8 days excluding suppression studies). The total daily

Full Text available with Trip Pro

1994 Antimicrobial agents and chemotherapy Controlled trial quality: uncertain

529. A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. (PubMed)

A double blind, placebo-controlled study to assess the effect of famciclovir on virus replication in patients with chronic hepatitis B virus infection. This is the first double-blind controlled study of famciclovir, an oral antiviral agent, as potential therapy for chronic hepatitis B virus (HBV) carries. A fall of more than 90% in HBV DNA levels was noted in six of 11 evaluable patients treated with a 10 day course of oral famciclovir. Further studies with more prolonged therapy are ongoing.

1996 Journal of viral hepatitis Controlled trial quality: uncertain

530. Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. (PubMed)

Famciclovir for the suppression of symptomatic and asymptomatic herpes simplex virus reactivation in HIV-infected persons. A double-blind, placebo-controlled trial. Herpes simplex virus (HSV) infection is one of the most common opportunistic infections in HIV-infected persons. However, most documentation of the effectiveness of antiviral therapy in reducing HSV reactivation is anecdotal.To evaluate the quantitative effect of antiviral therapy on the frequency of HSV reactivation in HIV-infected (...) persons.Double-blind, placebo-controlled, crossover trial.Research clinic at a university hospital.48 persons (45 men and 3 women) who were HIV positive and HSV seropositive.Patients were randomly assigned to receive famciclovir, 500 mg orally twice daily, or placebo for 8 weeks. They then crossed over to receive the other regimen after a 1-week washout period.Patients obtained daily cultures of their perirectal, urethral, oral, and genital areas and kept dairy records of signs and symptoms of genital

1998 Annals of internal medicine Controlled trial quality: predicted high

531. Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia. (PubMed)

Economic evaluation of famciclovir in reducing the duration of postherpetic neuralgia. The economic impact of famciclovir therapy for postherpetic neuralgia (PHN) in patients with acute herpes zoster was studied. A decision-analytic model of the treatment of herpes zoster and PHN was used to compare the cost of PHN between patients treated with oral famciclovir 500 mg three times daily for seven days and patients not receiving any antiviral therapy. The effects of famciclovir on PHN (...) in the model were based on the results of a randomized, double-blind trial in 419 adult outpatients. The cost of the course of famciclovir therapy (21 tablets) was estimated as the sum of the drug's wholesale acquisition cost and the pharmacy dispensing cost. The cost of treating PHN (physician visits, medications, and miscellaneous nondrug therapy) was estimated by consulting a panel of physicians. According to the model, the cost of treating PHN was $85 lower per famciclovir recipient ($294

1997 American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists Controlled trial quality: uncertain

532. Postherpetic neuralgia: impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. (PubMed)

Postherpetic neuralgia: impact of famciclovir, age, rash severity, and acute pain in herpes zoster patients. New and previously reported analyses of the data from a placebo-controlled trial of famciclovir are reviewed in light of recently proposed recommendations for the analysis of pain in herpes zoster trials. The analyses examined the effect of famciclovir treatment on the duration of postherpetic neuralgia (PHN), which was defined as pain persisting after rash healing, pain persisting > 30 (...) days after study enrollment, or pain persisting > 3 months after study enrollment; the baseline characteristics of patients in the famciclovir and placebo groups who developed PHN; the impact of famciclovir treatment on the duration of PHN, while controlling for significant covariates; and the prevalence of PHN at monthly intervals from 30 to 180 days after enrollment. The results of these analyses indicated that greater age, rash severity, and acute pain severity are risk factors for prolonged PHN

1998 The Journal of infectious diseases Controlled trial quality: uncertain

533. Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: A double-blind, dose-ranging, placebo-controlled, multicenter trial. (PubMed)

Peroral famciclovir in the treatment of experimental ultraviolet radiation-induced herpes simplex labialis: A double-blind, dose-ranging, placebo-controlled, multicenter trial. Three doses of famciclovir were tested for treatment of experimental ultraviolet radiation (UVR)-induced herpes labialis. Patients received 125, 250, or 500 mg of famciclovir or placebo 3 times a day for 5 days beginning 48 h after UVR exposure, a model of early episodic intervention. Of 248 patients irradiated, 102 (...) developed lesions while on treatment. There were no significant differences between groups in the number of lesions. The mean maximal lesion size was reduced in a dose-proportional manner: 139, 105, 77, and 55 mm2 for the placebo and 125-, 250-, and 500-mg famciclovir groups, respectively (P=.040, linear regression). Median time to healing was faster in the 500-mg famciclovir group than in the placebo group, both by investigator (4 vs. 6 days, 33% reduction, P=.010) and patient assessment (3.0 vs. 5.8

Full Text available with Trip Pro

1999 The Journal of infectious diseases Controlled trial quality: predicted high

534. Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing. (PubMed)

Famciclovir prophylaxis of herpes simplex virus reactivation after laser skin resurfacing. Cutaneous laser resurfacing with carbon dioxide and erbium:YAG lasers has achieved remarkable clinical results with a relatively low risk of morbidity and complications. The incidence of herpes simplex virus (HSV) reactivation after resurfacing can be decreased by prophylaxis with antiviral agents. Famciclovir is effective in the suppression and treatment of HSV infections; however, no studies have (...) examined the optimum dosing regimen for HSV prophylaxis in laser resurfacing.The objective of this study was to determine the efficacy of 2 doses of famciclovir as prophylactic anti-HSV therapy during cutaneous laser resurfacing.Ninety-nine consecutive patients undergoing full-face laser or perioral resurfacing received either 500-mg or 250-mg famciclovir twice daily, beginning 24 hours prior to laser resurfacing and continuing for 10 days.No HSV recurrences were seen in 90% of patients receiving

1999 Dermatologic Surgery Controlled trial quality: uncertain

535. Famciclovir in chronic hepatitis B: results of a dose-finding study. (PubMed)

Famciclovir in chronic hepatitis B: results of a dose-finding study. Famciclovir, an orally available nucleoside analogue with potent in vitro activity against HBV, is being investigated for treatment of chronic hepatitis B.A dose-finding study was conducted in patients with hepatitis B e antigen present in serum. Patients received famciclovir 125 mg, 250 mg, 500 mg three times daily (tid) or placebo for 16 weeks, followed by 8 months post-treatment observation, and 16 weeks open-label (...) % of patients with pretreatment ALT>upper limit of normal (ULN) receiving famciclovir 500 mg tid, experienced sustained normalization of ALT at the end of the 8-month follow-up. Anti-HBe seroconversion occurred more frequently in patients receiving famciclovir 500 mg tid compared with placebo (p=0.04). Famciclovir was generally well tolerated; the incidence of adverse events was comparable to placebo. Exacerbation of liver disease or serious ALT flares were not observed.Famciclovir 500 mg three times daily

2000 Journal of hepatology Controlled trial quality: uncertain

536. Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. (PubMed)

Antiviral therapy for herpes zoster: randomized, controlled clinical trial of valacyclovir and famciclovir therapy in immunocompetent patients 50 years and older. To compare the efficacy and safety of valacyclovir hydrochloride and famciclovir for the treatment of herpes zoster.A double-blind, randomized, controlled, multicenter clinical trial in which patients received 7 days of treatment and were followed up for 24 weeks.Patients reported directly to specialist centers or were referred from (...) primary care centers.There were 597 otherwise healthy immunocompetent outpatients, aged 50 years and older, who presented within 72 hours of onset of zoster rash.Treatment with valacyclovir hydrochloride (1 g 3 times daily) or famciclovir (500 mg 3 times daily) for 7 days.Resolution of zoster-associated pain and postherpetic neuralgia, rash healing, and treatment safety.Intent-to-treat analysis did not detect statistically significant differences for valacyclovir vs famciclovir on resolution of zoster

2000 Archives of family medicine Controlled trial quality: predicted high

537. Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. (PubMed)

Combination therapy with lamivudine and famciclovir for chronic hepatitis B-infected Chinese patients: a viral dynamics study. In vitro studies have shown that lamivudine and penciclovir (the active metabolite of famciclovir) act synergistically to inhibit hepatitis B virus (HBV) replication. We compared the effectiveness of HBV viral suppression by lamivudine monotherapy versus lamivudine plus famciclovir combination therapy in Chinese patients with chronic HBV infection. Twenty-one Chinese (...) hepatitis B e antigen (HBeAg)-positive patients, with detectable HBV DNA (Digene Hybrid Capture II), were randomized to receive either lamivudine 150 mg/d orally (group 1, 9 patients) or lamivudine 150 mg/d plus famciclovir 500 mg 3 times a day orally (group 2, 12 patients) for 12 weeks, with a follow-up period of at least 16 weeks. Serial serum HBV-DNA levels were determined and a mathematical model with provision for incomplete inhibition of virus production during therapy was applied to analyze

Full Text available with Trip Pro

2000 Hepatology Controlled trial quality: uncertain

538. A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. (PubMed)

A randomized, placebo-controlled study to evaluate the efficacy of 12-month famciclovir treatment in patients with chronic hepatitis B e antigen-positive hepatitis B. We conducted a randomized, placebo-controlled clinical study evaluating famciclovir (500 mg 3 times daily and 1.5 g once daily) for 1 year (6 months post-treatment follow-up) in patients with chronic hepatitis B e antigen (HBeAg)-positive hepatitis B virus (HBV) infection. The study was conducted in 80 centers in North America (...) , Europe, and Australia/New Zealand. A total of 417 patients with histologically documented chronic hepatitis B (histologic activity index [HAI] 9.5-11.0) received famciclovir (500 mg 3 times daily or 1.5 g once daily) or placebo. Famciclovir 500 mg 3 times daily significantly reduced HBV DNA and median HAI scores versus placebo. By week 8, median HBV DNA decreased from 1,645 to 283 MEq/mL (famciclovir 500 mg 3 times daily) and from 1,147 to 304 MEq/mL (famciclovir 1.5 g once daily), while increasing

Full Text available with Trip Pro

2000 Hepatology Controlled trial quality: uncertain

539. Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study. (PubMed)

Famciclovir for ophthalmic zoster: a randomised aciclovir controlled study. To compare the efficacy and safety of famciclovir with aciclovir for the treatment of ophthalmic zoster.Randomised, double masked, aciclovir controlled, parallel group in 87 centres worldwide including 454 patients with ophthalmic zoster of trigeminal nerve (V(1)) comprised the intent to treat population. Oral famciclovir 500 mg three times daily or oral aciclovir 800 mg five times daily for 7 days. Assessments included (...) day 0 (screening), days 3 and 7 (during treatment), days 10, 14, 21, 28 and monthly thereafter, up to 6 months (follow up). Proportion of patients who experienced ocular manifestations, severe manifestations and non-severe manifestations; loss of visual acuity was the main outcome measure.The percentage of patients who experienced one or more ocular manifestations was similar for famciclovir (142/245, 58.0%) and aciclovir (114/196, 58.2%) recipients, with no significant difference between groups

2001 British Journal of Ophthalmology Controlled trial quality: predicted high

540. Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. (PubMed)

Famciclovir vs. aciclovir in immunocompetent patients with recurrent genital herpes infections: a parallel-groups, randomized, double-blind clinical trial. Twice-daily therapy with famciclovir (FCV) was shown to be effective for episodic therapy for recurrent genital herpes in a large placebo-controlled trial. However, no study has been published to date comparing FCV and aciclovir (ACV).We have evaluated the effectiveness of FCV vs. ACV in the treatment of recurrent genital herpes infection.A

2001 The British journal of dermatology Controlled trial quality: predicted high

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>